CMS allows reimbursement for Spectrum cancer drug Zevalin

11/4/2009 | Reuters

The CMS approved reimbursement for Spectrum Pharmaceuticals' non-Hodgkin's lymphoma drug Zevalin, effective Jan. 1. The ruling removes "a significant historical barrier" to use of the drug, CEO Rajesh Shrotriya said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC